(Q33853109)

29 July 2017

1 reference

title

Management of patients with rising prostate-specific antigen after radical prostatectomy (English)

1 reference

29 July 2017

Laufer M

1

1 reference

29 July 2017

Pound CR

series ordinal

2

1 reference

29 July 2017

Carducci MA

series ordinal

3

1 reference

29 July 2017

Eisenberger MA

series ordinal

4

1 reference

29 July 2017

language of work or name

English

0 references

publication date

1 March 2000

1 reference

29 July 2017

1 reference

29 July 2017

55

1 reference

29 July 2017

3

1 reference

29 July 2017

309-315

1 reference

29 July 2017

Cancer statistics, 1999.

1 reference

https://api.crossref.org/works/10.1016%2FS0090-4295%2899%2900465-3

7 January 2021

Epidemiological trends and financial outcomes in radical prostatectomy among Medicare beneficiaries, 1991 to 1993.

1 reference

https://api.crossref.org/works/10.1016%2FS0090-4295%2899%2900465-3

7 January 2021

The Clinical Usefulness of Prostate Specific Antigen: Update 1994

1 reference

https://api.crossref.org/works/10.1016%2FS0090-4295%2899%2900465-3

7 January 2021

Prostate specific antigen: not detectable despite tumor progression after radical prostatectomy

1 reference

https://api.crossref.org/works/10.1016%2FS0090-4295%2899%2900465-3

7 January 2021

Prostate-specific antigen after anatomic radical retropubic prostatectomy. Patterns of recurrence and cancer control

1 reference

https://api.crossref.org/works/10.1016%2FS0090-4295%2899%2900465-3

7 January 2021

Postoperative nomogram for disease recurrence after radical prostatectomy for prostate cancer

1 reference

https://api.crossref.org/works/10.1016%2FS0090-4295%2899%2900465-3

7 January 2021

Long-Term (15 Years) Results After Radical Prostatectomy For Clinically Localized (Stage T2c Or Lower) Prostate Cancer

1 reference

https://api.crossref.org/works/10.1016%2FS0090-4295%2899%2900465-3

7 January 2021

Prediction of progression following radical prostatectomy. A multivariate analysis of 721 men with long-term follow-up

1 reference

https://api.crossref.org/works/10.1016%2FS0090-4295%2899%2900465-3

7 January 2021

Correlation of clinical and pathologic factors with rising prostate-specific antigen profiles after radical prostatectomy alone for clinically localized prostate cancer

1 reference

https://api.crossref.org/works/10.1016%2FS0090-4295%2899%2900465-3

7 January 2021

Prognostic significance of positive surgical margins in radical prostatectomy specimens

1 reference

https://api.crossref.org/works/10.1016%2FS0090-4295%2899%2900465-3

7 January 2021

Selection of men at high risk for disease recurrence for experimental adjuvant therapy following radical prostatectomy

1 reference

https://api.crossref.org/works/10.1016%2FS0090-4295%2899%2900465-3

7 January 2021

Assessment of the biologic markers p53, Ki-67, and apoptotic index as predictive indicators of prostate carcinoma recurrence after surgery

1 reference

https://api.crossref.org/works/10.1016%2FS0090-4295%2899%2900465-3

7 January 2021

Independent Prognostic Value of the 67-kd Laminin Receptor in Human Prostate Cancer

1 reference

https://api.crossref.org/works/10.1016%2FS0090-4295%2899%2900465-3

7 January 2021

Tumor angiogenesis correlates with progression after radical prostatectomy but not with pathologic stage in Gleason sum 5 to 7 adenocarcinoma of the prostate

1 reference

https://api.crossref.org/works/10.1016%2FS0090-4295%2899%2900465-3

7 January 2021

The value of serum prostate specific antigen determinations before and after radical prostatectomy

1 reference

https://api.crossref.org/works/10.1016%2FS0090-4295%2899%2900465-3

7 January 2021

Natural history of progression after PSA elevation following radical prostatectomy

1 reference

https://api.crossref.org/works/10.1016%2FS0090-4295%2899%2900465-3

7 January 2021

Early detection of residual prostate cancer after radical prostatectomy by an ultrasensitive assay for prostate specific antigen

1 reference

https://api.crossref.org/works/10.1016%2FS0090-4295%2899%2900465-3

7 January 2021

Early detection of recurrent prostate cancer with an ultrasensitive chemiluminescent prostate-specific antigen assay

1 reference

https://api.crossref.org/works/10.1016%2FS0090-4295%2899%2900465-3

7 January 2021

NONPROSTATIC SOURCES OF PROSTATE-SPECIFIC ANTIGEN

1 reference

https://api.crossref.org/works/10.1016%2FS0090-4295%2899%2900465-3

7 January 2021

Radical prostatectomy: transrectal sonographic evaluation to assess for local recurrence

1 reference

https://api.crossref.org/works/10.1016%2FS0090-4295%2899%2900465-3

7 January 2021

Sensitivity of computed tomography in detecting local recurrence of prostatic carcinoma following radical prostatectomy

1 reference

https://api.crossref.org/works/10.1016%2FS0090-4295%2899%2900465-3

7 January 2021

111Indium-capromab pendetide in the evaluation of patients with residual or recurrent prostate cancer after radical prostatectomy. The ProstaScint Study Group

1 reference

https://api.crossref.org/works/10.1016%2FS0090-4295%2899%2900465-3

7 January 2021

Evaluation of serum prostate-specific antigen velocity after radical prostatectomy to distinguish local recurrence from distant metastases

1 reference

https://api.crossref.org/works/10.1016%2FS0090-4295%2899%2900465-3

7 January 2021

Recurrence patterns after radical retropubic prostatectomy: clinical usefulness of prostate specific antigen doubling times and log slope prostate specific antigen

1 reference

https://api.crossref.org/works/10.1016%2FS0090-4295%2899%2900465-3

7 January 2021

Local recurrence after radical prostatectomy: characteristics in size, location, and relationship to prostate-specific antigen and surgical margins

1 reference

https://api.crossref.org/works/10.1016%2FS0090-4295%2899%2900465-3

7 January 2021

Results of radical prostatectomy in men with clinically localized prostate cancer

1 reference

https://api.crossref.org/works/10.1016%2FS0090-4295%2899%2900465-3

7 January 2021

Long-term results of radiation therapy for prostate cancer recurrence following radical prostatectomy

1 reference

https://api.crossref.org/works/10.1016%2FS0090-4295%2899%2900465-3

7 January 2021

Preirradiation PSA predicts biochemical disease-free survival in patients treated with postprostatectomy external beam irradiation

1 reference

https://api.crossref.org/works/10.1016%2FS0090-4295%2899%2900465-3

7 January 2021

Adjuvant and salvage irradiation following radical prostatectomy for prostate cancer

1 reference

https://api.crossref.org/works/10.1016%2FS0090-4295%2899%2900465-3

7 January 2021

Effect of combined transient androgen deprivation and irradiation following radical prostatectomy for prostatic cancer

1 reference

https://api.crossref.org/works/10.1016%2FS0090-4295%2899%2900465-3

7 January 2021

How much can we rely on the level of prostate-specific antigen as an end point for evaluation of clinical trials? A word of caution!

1 reference

https://api.crossref.org/works/10.1016%2FS0090-4295%2899%2900465-3

7 January 2021

Suramin blockade of insulinlike growth factor I-stimulated proliferation of human osteosarcoma cells

1 reference

https://api.crossref.org/works/10.1016%2FS0090-4295%2899%2900465-3

7 January 2021

Basic fibroblast growth factor levels in cancer cells and in sera of patients suffering from proliferative disorders of the prostate

1 reference

https://api.crossref.org/works/10.1016%2FS0090-4295%2899%2900465-3

7 January 2021

10.1016/S0090-4295(99)00465-3

Identifiers

DOI

1 reference

29 July 2017

1 reference